Literature DB >> 22705114

Preperitoneal single-port transvesical enucleation of the prostate (STEP) for large-volume BPH: one-year follow-up of Qmax, IPSS, and QoL.

Linhui Wang1, Bing Liu, Qing Yang, Zhenjie Wu, Bo Yang, Zunli Xu, Chen Cai, Liang Xiao, Wei Chen, Yinghao Sun.   

Abstract

OBJECTIVE: To evaluate the 1-year efficacy and safety of single-port transvesical enucleation of the prostate (STEP) for voluminous benign prostatic hyperplasia (BPH).
METHODS: Nine patients with moderate- to large-volume (83.8 ± 19.9 mL) BPH (mean age 71.9 ± 6.39 years, body mass index [BMI] 21.5 ± 3.25 kg/m(2)) were preoperatively evaluated by abdominal and transrectal ultrasonography, uroflowmetry, International Prostate Symptom Score (IPSS) and Quality of Life Index (QoL). The STEP procedures were performed by a single surgeon. All patients were followed up for a minimum of 12 months postoperatively by ultrasonography, uroflowmetry, IPSS, and QoL.
RESULTS: STEP was smoothly completed in 8 cases with 1 case of open conversion owing to failure of the single-port device insertion. The mean operative duration was 160.9 ± 30.24 minutes, and the estimated blood loss was 418.8 ± 282.76 mL. One intraoperative complication of bleeding occurred. Postoperative complications occurred for 2 patients, including one case each of acute epididymitis and urethral stricture. At the 12-month follow-up after surgery, the mean Q(max) of the entire cohort was 22.7 ± 4.62 mL/s (an increase of 12.9 mL/s), with an average postvoid residual volume of 36.1 ± 40.02 mL, an IPSS of 4.1 ± 1.36 (a decrease of 21 points), and a QoL of 1.4 ± 1.19 (a decrease of 3.2 points). No patients developed incontinence or bladder neck contracture.
CONCLUSION: In selected patients with voluminous BPH, STEP is a safe, feasible, and efficacious procedure with a promising outcome at 1-year follow-up in terms of Q(max), IPSS, and QoL.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22705114     DOI: 10.1016/j.urology.2012.02.064

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

Review 1.  Transurethral enucleation of the prostate versus transvesical open prostatectomy for large benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Youcheng Lin; Xun Wu; Abai Xu; Rui Ren; Xueqiong Zhou; Yong Wen; Yong Zou; Mancheng Gong; Chunxiao Liu; Zexuan Su; Thomas R W Herrmann
Journal:  World J Urol       Date:  2015-12-23       Impact factor: 4.226

2.  Incidence and risk factors for postoperative urinary incontinence after various prostate enucleation procedures: systemic review and meta-analysis of PubMed literature from 2000 to 2021.

Authors:  Mohammad Hout; Aaron Gurayah; Maria Camila Suarez Arbelaez; Ruben Blachman-Braun; Khushi Shah; Thomas R W Herrmann; Hemendra N Shah
Journal:  World J Urol       Date:  2022-10-04       Impact factor: 3.661

Review 3.  Outcomes of minimally invasive simple prostatectomy for benign prostatic hyperplasia: a systematic review and meta-analysis.

Authors:  Ilaria Lucca; Shahrokh F Shariat; Sebastian L Hofbauer; Tobias Klatte
Journal:  World J Urol       Date:  2014-05-31       Impact factor: 4.226

4.  'Minimum-incision' endoscopically assisted transvesical prostatectomy: Surgical technique and early outcomes.

Authors:  Tarek M El-Karamany; Ahmed M Al-Adl; Shabieb A Abdel-Baky; Abdallah F Abdel-Azeem; Mohamed A Zaazaa
Journal:  Arab J Urol       Date:  2014-04-28

5.  Transvesical open prostatectomy for benign prostatic hyperplasia in the era of minimally invasive surgery: Perioperative outcomes of a contemporary series.

Authors:  Ahmed M Elshal; Ahmed R El-Nahas; Tamer S Barakat; Mohamed M Elsaadany; Ahmed S El-Hefnawy
Journal:  Arab J Urol       Date:  2013-07-31

Review 6.  Laparoscopic Approach for Intravesical Surgery Using Pneumovesicum in Urology: Literature Review.

Authors:  Bum Sik Tae; Hoon Choi; Jae Young Park; Jae Hyun Bae
Journal:  Int Neurourol J       Date:  2018-01-31       Impact factor: 2.835

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.